Depletion of hepatocyte nuclear estrogen receptor expression is associated with promotion of tamoxifen induced GST-P foci to tumours in rat liver

Carcinogenesis

Volumn 18, Issue 5, 1997, Pages 1109-1112

  Carthew, P ^a   Edwards, R E ^a   Nolan, B M ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; CELL NUCLEUS RECEPTOR; ESTROGEN RECEPTOR; GLUTATHIONE TRANSFERASE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOHISTOLOGY; LIVER ADENOMA; LIVER CARCINOGENESIS; LIVER CARCINOMA; LIVER CELL; MALE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; RAT;

ADENOMA; AFLATOXINS; ANIMALS; CARCINOMA; CELL COMPARTMENTATION; CELL NUCLEUS; DIMETHYLNITROSAMINE; FEMALE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; ISOENZYMES; LIVER; LIVER NEOPLASMS; MALE; PRECANCEROUS CONDITIONS; RATS; RATS, INBRED F344; RECEPTORS, ESTROGEN; TAMOXIFEN; THIOACETAMIDE;

EID: 0031426677     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/18.5.1109     Document Type: Article

References (23)

1. Pitot, H.C. (1988) Hepatic neoplasia: chemical induction. In Arias, I.M., Jakoby, W.B., Popper, H., Schachter, D. and Shafitz, D.A. (eds) The Liver: Biology and Pathobiology. Raven Press, New York, Second edition, Chapter 64.
2. Maronpot, R.R., Pitot, H.C. and Peraino, C. (1989) Use of rat liver altered focus models for testing chemicals that have completed two year carcinogenicity studies. Toxicologic Pathology, 17, 651-663.
3. Imaida, K., Tatematsu, M., Kato, T, Tsuda, H. and Ito, N. (1989) Advantages and limitations of stereologial estimation of placental glutathione s-transferase-positive rat liver cell foci by computerized three-dimensional reconstruction. Cancer Res., 80, 326-330.
4. Ito, N., Tatematsu, M., Hasegawa, R. and Tsuda, H. (1989) Medium-term bioassay system for detection of carcinogens and modifers of hepatocarcinogenesis utilizing the GST-P positive liver cell focus as an endpoint marker. Toxicol. Pathol., 17, 630-641.
5. Greaves, S., Goonetilleke, R., Nunn, G., Topham, J. and Orton, T. (1993) Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res., 53, 3919-3924.
6. Williams, G.M., Iatropoulos, M.J., Djordjevic, M.V. and Kaltenberg, O.P. (1993) The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis, 14, 315-317.
7. Hard, G.C., Iatropoulos, M.J., Jordon, K., Radi, L., Kalterberg, O.P., Imondi, A.R. and Williams, G.M. (1993) Major differences in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl: CD(BR) rats. Cancer Res., 53, 4534-4541.
8. 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumour formation. Carcinogenesis, 16, 1299-1304.
9. Carthew, P., Martin, E.A., White, I.N.W., Edwards, R.E., Dorman, B.M. and Smith, L.L. (1995) Tamoxifen induces short-term cumulative DNA damage and liver tumours, with and without promotion by phenobarbital. Cancer Res., 55, 544-547.
10. Phillips, D.H., Carmichael, P.L., Hewer, A., Cole, K.J. and Poon, G.K. (1994) α-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA binding activity in rat hepatocytes. Cancer Res., 54, 5518-5522.
11. Phillips, D.H., Hewer, A., White, I.N.H. and Farmer, P.B. (1994) Co-chromatography of a tamoxifen epoxide deoxyguanylic acid adduct with a major DNA adduct formed in the livers of tamoxifen treated rats. Carcinogenesis, 15, 793-795.
12. Carthew, P. Nolan, B.M. Edwards, R.E. and Smith, L.L. (1996) The role of cell death and cell proliferation in the promotion of rat liver tumours by tamoxifen. Cancer Lett., 106, 163-169.
13. Vancutsem, P.M., Lazarus, P. and Williams, G.M. (1994) Frequent and specific mutations of the rat p53 gene in hepatocarcinogenesis induced by tamoxifen. Cancer Res., 54, 3864-3867.
14. Conte, D., Neri, A., Fracchiolla, N.S., Croce, L.S., Lodi, L., Fraquelli, M., Masutti, F. and Tiribelli, C. (1994) Analysis of p53 and ras gene mutations in hepatocellular carcinoma in Italy. Hepatology, 6, 1005-1008.
15. Leon, M. and Kew, M.C. (1995) Analysis of ras gene mutations in hepatocellular carcinoma in southern African blacks. Anticancer Res., 15, 859-861.
16. Fowler, M.L., Sigler, R.E., De la Iglesia, F.A., Reddy, J.K. and Lalwani, N.D. (1995) Absence of Ki-ras mutations in exocrine pancreatic tumors from male rats chronically exposed to gabapentin. Mutation Res. Fund. Mol. Mech. Mutagen., 327, 151-160.
17. Maronpot, R.R., Fox, T., Malarkey, D.E. and Goldsworthy, T.L. (1995) Mutations in the ras proto-oncogene: clues to etiology and molecular pathogenesis of mouse liver tumors. Toxicology, 101, 125-156.
18. Yager, J.D., Zurlo, J. and Ni, N. (1991) Sex hormones and tumor promotion in liver. Proc. Soc. Expt. Biol. Med., 198, 667-674.
19. Maronpot, R.R., Montgomery, C.A., Boorman, G.A. and McConnell, E.E. (1986) National toxicology program nomenclature for hepatoproliferative lesions of rats. Toxicologic Path., 14, 263-273.
20. Porter, L.E., Elm, M.S., Van Thiel, D.H. and Eagon, P.K. (1987) Hepatic estrogen receptor in human liver disease. Gastroentemlogy, 92, 735-745.
21. Eagon, P.K., Francavilla, A., DiLeo, A., Elm, M.S., Gennari, L., Mazzoferro, V., Colella, G., Van Thiel, D.H. and Starzl, T.E. (1991) Quantation of estrogen and androgen receptors in hepatocellular carcinoma and adjacent normal human liver. Dig. Dis. Sci., 36, 1303-1308.
22. Eagon, P.K., Elm, M.S., Epley, M.J., Shinozuka, H. and Rao, K.N. (1996) Sex steroid metabolism and receptor status in hepatic hyperplasia and cancer in rats. Gasteroenterology, 110, 1199-1207.
23. Villa, E., Camellini, L., Dugani, A., Zucchi, F., Grottola, A., Merighi, A., Buttafoco, P., Losi, L. and Manenti, F. (1995) Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. Cancer Res., 55, 498-500.